Short answer
Fulcrum Therapeutics, Inc. (FULC) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Principal accounting officer Greg Tourangeau departing Fulcrum on August 7, 2026.
Fulcrum Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Principal accounting officer Greg Tourangeau departing Fulcrum on August 7, 2026
- CFO Alan Musso appointed principal accounting officer effective August 7, 2026
- Appointment consolidates CFO and accounting oversight under Musso
- No additional compensation, related-party transaction, or family relationship disclosed for Musso
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Fulcrum Therapeutics, Inc. 8-K filings
Get the next FULC 8-K as it lands
Follow FULC for push alerts, or ask the research agent what this filing means.